When comparing Gadolinium-Prostate Specific Membrane Antigen (Ga-PSMA) PET/CT with ferumoxtran-10 NP-enhanced MRI in prostate cancer lymph node assessment, both modalities identified suspicious lymph nodes that were unnoticed by the other, with the latter proving better in detecting smaller suspicious lymph nodes, suggesting a complementary role.109 An ongoing phase 3 trial110 is putting ferumoxtran-10's ability to the test against unenhanced MRI. The gene discussed is FOLH1; the disease is prostate carcinoma.